Atlas Trials

A Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy and Immunogenicity of a Tumor Vaccine Injection Targeting Stressinducible Proteins MICA/B in Combination With the AG Regimen in Patients With Metastatic Pancreatic Cancer

Clinical trial NCT07231094 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07231094
Sponsor
The Third Xiangya Hospital of Central South University
Status
NOT_YET_RECRUITING
Phase
Early Phase 1
Study type
INTERVENTIONAL
Pancreatic Cancer Metastatic
Start date
2025-11-01
Primary completion
2027-11-01
Enrollment
13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.